OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The...OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The goal of this article is to evaluate comprehensively the efficacy and safety of nerve growth factor for the treatment of neurological diseases. DATA RETRIEVAL： A computer-based retrieval was performed from six databases, including the Cochrane Library, PubMed, EMBASE, Sino Med, CNKI, and the VIP database, searching from the clinical establishment of nerve growth factor for treatment until December 31, 2013. The key words for the searches were ＂nerve growth factor, randomized controlled trials＂ in Chinese and in English. DATA SELECTION： Inclusion criteria： any study published in English or Chinese referring to randomized controlled trials of nerve growth factor; patients with neurological diseases such as peripheral nerve injury, central nerve injury, cranial neuropathy, and nervous system infections; patients older than 7 years; similar research methods and outcomes assessing symptoms; and measurement of nerve conduction velocities. The meta-analysis was conducted using Review Manager 5.2.3 software. MAIN OUTCOME MEASURES： The total effective rate, the incidence of adverse effects, and the nerve conduction velocity were recorded for each study. RESULTS： Sixty-four studies involving 6,297 patients with neurological diseases were included. The total effective rate in the group treated with nerve growth factor was significantly higher than that in the control group （P 〈 0.0001, RR： 1.35, 95%CI： 1.30-1.40）. The average nerve conduction velocity in the nerve growth factor group was significantly higher than that in the control group （P 〈 0.00001, MD. 4.59 m/s, 95%CI： 4.12-5.06）. The incidence of pain or sclero- ma at the injection site in the nerve growth factor group was also higher than that in the control group （P 〈 0.00001, RR： 6.30, 95%CI： 3.53-11.27）, but s展开更多
目的:分析温肾类汤剂治疗PMOP的疗效和可能发生的不良反应。方法:电子检索9个国内外相关数据库,检索日期截止至2015年9月,并根据Cochrane Handbook 5.1评价标准和工具评价纳入研究的质量,并用Rev Man 5.3软件进行Meta分析。结果:共纳入4...目的:分析温肾类汤剂治疗PMOP的疗效和可能发生的不良反应。方法:电子检索9个国内外相关数据库,检索日期截止至2015年9月,并根据Cochrane Handbook 5.1评价标准和工具评价纳入研究的质量,并用Rev Man 5.3软件进行Meta分析。结果:共纳入44项研究包括3878例患者,多数温肾类汤剂在提高患者血清雌二醇水平方面可能优于常规西药治疗,如疗程6个月时,温肾类汤剂对比常规西药提高患者血清雌二醇水平的WMD和95%CI为[3.2(0.43,5.97)];温肾类汤剂提高机体各部位骨密度水平可能优于温肾类中成药治疗,如疗程6个月时温肾类汤剂对比温肾类中成药提高患者腰椎骨密度WMD和95%CI为[1.38(0.13,1.63)];在调节患者血磷、血钙水平方面,因研究数较少或结论不一致尚未发现较明显的趋势。此外,温肾类汤剂治疗时未发现明显副作用。结论:依据现有临床研究资料分析温肾类汤剂治疗PMOP有临床意义,以温补肾阳为具体治法有一定疗效,汤剂较成药对部分症状的改善效果更佳。但因纳入研究质量以及临床疗效证据十分有限,需要更多设计严谨、实施严格、规模较大的临床研究加以证实。展开更多
目的:评价术前放化疗联合手术治疗(neoadjuvant chemoradiotherapy and surgery,CRT+S)与单纯手术治疗(surgery,S)对可切除食管鳞癌患者生存及手术的影响。方法:检索PubMed系统中所有CRT+S与S治疗可切除食管鳞癌的随机对照研究(randomiz...目的:评价术前放化疗联合手术治疗(neoadjuvant chemoradiotherapy and surgery,CRT+S)与单纯手术治疗(surgery,S)对可切除食管鳞癌患者生存及手术的影响。方法:检索PubMed系统中所有CRT+S与S治疗可切除食管鳞癌的随机对照研究(randomized controlled trial,RCT),应用RevMan 5.2软件进行Meta分析。结果:共纳入10篇文献。CRT+S与S组比较:1)患者1年生存率差异无统计学意义,RR=1.03,95%CI为0.96～1.10,P=0.37。2)CRT+S组提高了3、5年生存率,3年RR=1.32,95%CI为1.17～1.50,P<0.001;5年RR=1.24,95%CI为1.03～1.49,P=0.02。3)相比于S组,CRT+S组的手术率较低,RR=0.84,95%CI为0.72～0.99,P=0.04;术后并发症的发生率较高,RR=1.25,95%CI为1.02～1.53,P=0.03;死亡率也较高,RR=2.34,95%CI为1.37～3.99,P=0.002;但提高了R0切除率,RR=1.18,95%CI为1.06～1.32,P=0.002。4)术后局部复发率差异无统计学意义,RR=0.82,95%CI为0.31～2.16,P=0.68;术后远处转移率差异无统计学意义,RR=0.86,95%CI为0.60～1.22,P=0.39。结论:CRT+S治疗明显提高了可切除食管鳞癌患者的长期生存率及R0切除率。展开更多
基金supported by the National Science and Technology Major Projects for "Major New Drugs Innovation and Development",No.2012ZX09201-301-005
文摘OBJECTIVE： China is the only country where nerve growth factor is approved for large-scale use as a clinical medicine. More than 10 years ago, in 2003, nerve growth factor injection was listed as a national drug. The goal of this article is to evaluate comprehensively the efficacy and safety of nerve growth factor for the treatment of neurological diseases. DATA RETRIEVAL： A computer-based retrieval was performed from six databases, including the Cochrane Library, PubMed, EMBASE, Sino Med, CNKI, and the VIP database, searching from the clinical establishment of nerve growth factor for treatment until December 31, 2013. The key words for the searches were ＂nerve growth factor, randomized controlled trials＂ in Chinese and in English. DATA SELECTION： Inclusion criteria： any study published in English or Chinese referring to randomized controlled trials of nerve growth factor; patients with neurological diseases such as peripheral nerve injury, central nerve injury, cranial neuropathy, and nervous system infections; patients older than 7 years; similar research methods and outcomes assessing symptoms; and measurement of nerve conduction velocities. The meta-analysis was conducted using Review Manager 5.2.3 software. MAIN OUTCOME MEASURES： The total effective rate, the incidence of adverse effects, and the nerve conduction velocity were recorded for each study. RESULTS： Sixty-four studies involving 6,297 patients with neurological diseases were included. The total effective rate in the group treated with nerve growth factor was significantly higher than that in the control group （P 〈 0.0001, RR： 1.35, 95%CI： 1.30-1.40）. The average nerve conduction velocity in the nerve growth factor group was significantly higher than that in the control group （P 〈 0.00001, MD. 4.59 m/s, 95%CI： 4.12-5.06）. The incidence of pain or sclero- ma at the injection site in the nerve growth factor group was also higher than that in the control group （P 〈 0.00001, RR： 6.30, 95%CI： 3.53-11.27）, but s
文摘目的:分析温肾类汤剂治疗PMOP的疗效和可能发生的不良反应。方法:电子检索9个国内外相关数据库,检索日期截止至2015年9月,并根据Cochrane Handbook 5.1评价标准和工具评价纳入研究的质量,并用Rev Man 5.3软件进行Meta分析。结果:共纳入44项研究包括3878例患者,多数温肾类汤剂在提高患者血清雌二醇水平方面可能优于常规西药治疗,如疗程6个月时,温肾类汤剂对比常规西药提高患者血清雌二醇水平的WMD和95%CI为[3.2(0.43,5.97)];温肾类汤剂提高机体各部位骨密度水平可能优于温肾类中成药治疗,如疗程6个月时温肾类汤剂对比温肾类中成药提高患者腰椎骨密度WMD和95%CI为[1.38(0.13,1.63)];在调节患者血磷、血钙水平方面,因研究数较少或结论不一致尚未发现较明显的趋势。此外,温肾类汤剂治疗时未发现明显副作用。结论:依据现有临床研究资料分析温肾类汤剂治疗PMOP有临床意义,以温补肾阳为具体治法有一定疗效,汤剂较成药对部分症状的改善效果更佳。但因纳入研究质量以及临床疗效证据十分有限,需要更多设计严谨、实施严格、规模较大的临床研究加以证实。
